Form 4 Viatris Inc For: 3 October By Investing.com
The article reports on a Form 4 filing for Viatris Inc. (VTRS) dated October 3. It includes Viatris's stock performance, showing a 0.80% gain, and displays a variety of financial market data for indices, commodities, and bonds, alongside trending stocks and general news headlines.
Form 4 Viatris Inc For: 3 October By Investing.com
This article from Investing.com announces the filing of a Form 4 for Viatris Inc. on October 3rd. Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of the company's securities. The article provides this single piece of information without further detail.
Form 4 Viatris Inc For: 3 October By Investing.com
This article announces the filing of a Form 4 for Viatris Inc. on October 3. It provides no further details about the Form 4 itself but includes various market data and related news headlines from Investing.com. The information is presented in a news snippet format with stock market updates.
Form 4 Viatris Inc For: 3 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Viatris Inc., dated October 3rd. Form 4s disclose changes in beneficial ownership of securities by a company's insiders. The article provides the title and date of the filing, along with the stock symbol VTRS and its current performance.
PFE5003242 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the PFE5003242 bond issued by Viatris, Inc. It outlines key bond details such as issuer information, issue and maturity dates, face value, and minimum denomination. The profile also includes a comprehensive interest payment schedule with upcoming and past payouts, as well as redemption information.
Jazz Pharmaceuticals (JAZZ), The Latest Update Raises A Bigger Question
Jazz Pharmaceuticals reported strong quarterly revenue of US$1.21 billion, exceeding forecasts and leading to higher full-year guidance. Despite this positive financial update, the stock price has fallen, prompting investors to re-evaluate how much of the company's earnings strength was already factored into its valuation after a significant year-to-date return. The company is considered 19% undervalued with an implied fair value of $289.45, driven by anticipated new therapy approvals and expansion in its neuroscience/sleep portfolio, though risks such as patent expiries and potential underdelivery of new launches remain.
Viatris Inc. (VTRS) stock price, news, quote and history
This article provides a comprehensive overview of Viatris Inc. (VTRS) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's operations as a healthcare provider specializing in prescription brand drugs, generic drugs, and biosimilars across various global markets. Key financial metrics, recent news, and performance comparisons against the S&P 500 are also included.
Return on invested capital % of Viatris, Inc. – HAN:VIA
This article provides financial information for Viatris, Inc. (HAN:VIA) specifically focusing on its Return on Invested Capital (ROIC) percentage. It indicates that the market was closed with no trades at the time of publication and offers financial data through TradingView.
Net income before discontinued operations of Viatris, Inc. – HAN:VIA
This page displays financial data for Viatris, Inc. (HAN:VIA) specifically focusing on its net income before discontinued operations. The content is part of a larger financial data platform, likely TradingView, offering an overview of the company's financials on the Hannover Stock Exchange.
Equity in earnings of Viatris, Inc. – HAN:VIA
This article from TradingView provides a financial overview of Viatris, Inc. (HAN:VIA) on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades. The primary content focuses on the "Equity in earnings" section for the company.
Viatris named to Forbes' World's Best Employers list for sixth year, highlighting strong workplace culture.
Viatris Inc. has been recognized on Forbes' World's Best Employers list for the sixth consecutive year, a testament to its strong workplace culture and employee satisfaction based on independent feedback. This achievement reinforces the company's commitment to innovation and sustainability within the global healthcare sector. Despite this positive recognition, Viatris's stock experienced a slight decline.
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
Viatris has been named to Forbes' World's Best Employers list for the sixth consecutive year, based on independent employee feedback. This recognition highlights the company's strong workplace culture, employee trust, and dedication to its global workforce. Viatris attributes this achievement to its colleagues' ingenuity and collaborative efforts in making a positive impact on patients' lives worldwide.
Viatris stock hits 52-week high at 18.4 USD By Investing.com
Viatris Inc. stock reached a new 52-week high of $18.40, marking an 85.45% increase over the past year and a 42% gain in the last six months. This surge follows strong Q2 2026 financial results, which exceeded Wall Street expectations, and positive analyst coverage with Oppenheimer initiating an outperform rating. InvestingPro analysis suggests the stock remains undervalued, indicating continued investor confidence and robust market performance for the pharmaceutical company.
Viatris stock hits 52-week high at 18.4 USD
Viatris Inc. (VTRS) stock recently hit a 52-week high of $18.40, reflecting an impressive 85.45% increase over the past year and a 42% gain in the last six months. This surge follows strong Q2 2026 financial results, where the company surpassed Wall Street expectations and raised its full-year guidance. Analysts at Oppenheimer initiated coverage with an "outperform" rating, while Piper Sandler increased its price target, indicating growing investor confidence in Viatris's performance and pipeline.
Viatris stock hits 52-week high at 18.4 USD By Investing.com
Viatris Inc. (VTRS) stock reached a 52-week high of $18.40, reflecting an 85.45% increase over the past year and a 42% gain in the last six months. InvestingPro analysis suggests the stock is undervalued despite its "GOOD" financial health. This surge follows strong Q2 2026 financial results, raised full-year guidance, and positive analyst coverage, with Oppenheimer initiating an "outperform" rating and Piper Sandler increasing its price target.
Viatris stock hits 52-week high at 18.4 USD By Investing.com
Viatris Inc. stock has reached a new 52-week high of $18.40, reflecting an 85.45% increase over the past year and a 42% gain in the last six months. The company reported strong Q2 2026 financial results, exceeding analyst expectations, and subsequently raised its full-year guidance. Oppenheimer initiated coverage with an outperform rating and a $25 price target, while Piper Sandler raised its target to $13, both highlighting Viatris's potential for growth and undervaluation.
PFE5282056 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the PFE5282056 bond issued by Viatris, Inc., outlining its key facts such as issuer type, issue and maturity dates, face value, and minimum denomination. It also covers Viatris's company overview, bond classification, credit risk assessment, interest payment details including coupon rate and frequency, and redemption information. The bond has a 2.70% semi-annual fixed rate coupon and an outstanding amount of $1.45 billion USD.
Viatris Inc. stock rises Monday, outperforms market
Viatris Inc. stock (VTRS) rose 2.47% to $18.27 on Monday, outperforming the broader market which saw declines in the S&P 500 Index and Dow Jones Industrial Average. This marks the third consecutive day of gains for the stock.
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks Inc. has announced updated 2026 financial guidance and the final transaction details after completing its acquisition of Theravance Biopharma. The acquisition adds YUPELRI® to Zymeworks' portfolio, providing a durable cash flow source, and is expected to contribute immediately accretive revenue and cash flow. The company projects total revenue for 2026 to be between $278 million and $292 million and Adjusted EBITDA between $114 million and $128 million.
Viatris Inc Lobbying Profile, 2023
This OpenSecrets profile details Viatris Inc.'s federal lobbying activities for 2023, showing a total spending of $850,000 for direct lobbying efforts. The data, updated on July 23, 2026, includes spending from January 1 to June 30 for the current year and full-year spending for prior years. OpenSecrets compiles this information based on data from the Senate Office of Public Records, focusing on the pharmaceutical and health products industry.
Viatris Inc. (VTRS) stock price, news, quote and history
Viatris Inc. (VTRS) is a healthcare company that operates globally, manufacturing prescription brand drugs, generic drugs, complex generics, and biosimilars across various therapeutic areas. The article provides detailed financial information including its stock performance, market capitalization, earnings trends, analyst ratings, and a company overview. Viatris reported a Q2 FY26 revenue of $3.76 billion and an EPS (TTM) of -0.38, with analysts estimating a 1-year target price of $19.40.
Mylan asks US court to clear Wegovy generic from Novo patent claims
Generic drugmaker Viatris, through its Mylan Pharmaceuticals unit, has sued Novo Nordisk in Delaware federal court. Mylan is seeking a ruling that its proposed generic version of Novo's weight-loss drug Wegovy would not infringe Novo's patent covering the administration method of single-dose Wegovy pens. This comes as Novo Nordisk generated nearly $31 billion from its semaglutide-based weight loss drugs last year, with generic versions of Wegovy and Ozempic not expected until 2032 when core patents expire.
Viatris (VTRS) Q2 2026 Earnings Call Transcript
This article provides the transcript of Viatris's (VTRS) Q2 2026 earnings call, which took place on August 6, 2026, at 8:30 AM EDT. It lists the company participants, including the CEO and CFO, as well as several analysts from various financial institutions who were present on the call. The content is powered by Quartr.
VIAA Bond Profile: Coupon and Redemption
This article provides a detailed bond profile for Viatris Inc.'s 4.0% bond maturing on June 22, 2050 (VIAA), traded on the Dusseldorf Stock Exchange. It covers key facts about the bond and its issuer, Viatris, Inc., including its issue date, maturity date, face value, and minimum denomination. The profile also outlines coupon payment details, such as the fixed semi-annual coupon rate of 4.00%, and upcoming payout schedules, alongside bond redemption information.
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Alkermes reported early positive results for its investigational oral ADHD drug, ALKS 7290, showing symptom improvements in a small Phase 1b trial. While these initial findings support further development, the study was not powered to establish statistical significance over placebo. The company plans a larger Phase 2 trial with results expected in 2027 to determine efficacy and tolerability compared to placebo.
Viatris sues Novo Nordisk over generic Wegovy patent dispute
Viatris has filed a lawsuit against Novo Nordisk in a Delaware federal court, seeking a ruling that its generic version of Wegovy would not infringe Novo Nordisk's patent. The lawsuit specifically concerns a method of administering single-dose Wegovy pens for weight loss. Novo Nordisk's patents covering semaglutide, the active ingredient in Wegovy and Ozempic, are set to expire in 2032.
Viatris sues Novo Nordisk, seeks to market generic Wegovy
Viatris has filed a lawsuit against Novo Nordisk in a Delaware federal court, seeking permission to market a generic version of Novo Nordisk's weight-loss drug, Wegovy (semaglutide). The lawsuit, filed by Mylan (acquired by Viatris in 2020), argues against Novo Nordisk's patent protection for the blockbuster GLP-1 therapy. This legal challenge aims to open the market for a more affordable generic alternative.
Is Nuveen ESG Small-Cap ETF (NUSC) a Strong ETF Right Now?
The Nuveen ESG Small-Cap ETF (NUSC), launched in 2016, is a smart beta ETF focusing on the Style Box - Small Cap Growth category. Managed by Nuveen with over $1.25 billion in assets, NUSC aims to track the TIAA ESG Small-Cap Index and has an expense ratio of 0.31%. The article details its sector allocations, top holdings, performance, and compares it to alternative ESG ETFs.
Oppenheimer initiates Viatris stock with outperform rating By Investing.com
Oppenheimer has initiated coverage on Viatris Inc (NASDAQ:VTRS) with an outperform rating and a $25.00 price target, citing potential for significant upside despite an 85% return over the past year. The firm believes the market undervalues Viatris's improving core business, cost savings, and late-stage pipeline, including two potential blockbuster assets. This positive outlook is further supported by strong Q2 2026 financial results, which exceeded expectations, and a raised full-year guidance.
How Viatris Inc. (VTRS) Affects Rotational Strategy Timing
Viatris Inc. (VTRS) is showing strong near-term sentiment which could influence a mid-term neutrality towards a long-term positive bias. The analysis highlights an exceptional 27.2:1 risk-reward setup targeting an 8.2% gain against 0.3% risk. AI models have generated three distinct trading strategies for different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging, with specific entry zones, targets, and stop losses.
Oppenheimer initiates Viatris stock with outperform rating
Oppenheimer has initiated coverage on Viatris Inc. (NASDAQ:VTRS) with an "outperform" rating and a price target of $25.00, citing the company's improving base business, cost savings, and a promising late-stage pipeline. Despite the market viewing Viatris as a declining generics company, Oppenheimer believes growth drivers like new products and cost efficiencies will lead to faster EBITDA and EPS growth. This positive outlook is supported by recent strong financial results for Viatris, which surpassed Q2 2026 expectations and raised full-year guidance.
Oppenheimer initiates Viatris stock with outperform rating By Investing.com
Oppenheimer initiated coverage on Viatris Inc (NASDAQ:VTRS) with an outperform rating and a $25.00 price target, citing an improving base business, cost savings, and a promising late-stage pipeline despite the market's perception of the company as a declining generics firm. The firm expects revenue growth from Greater China and new products, with EBITDA and EPS driven by cost savings and share repurchases. InvestingPro analysis also suggests the stock is undervalued, supported by aggressive share buybacks and strong financial performance in Q2 2026.
Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations
Viatris Inc. (VTRS) is a global pharmaceutical company with a market capitalization of $19.47 billion, trading at $16.95 with a potential upside of 10.78% based on analyst targets. Despite a negative EPS, the company shows a low forward P/E of 6.37 and robust free cash flow of over $2.67 billion. Strategic collaborations and a diverse portfolio in various therapeutic areas position Viatris for potential growth in the healthcare sector.
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
Viatris Inc. (VTRS) has received approval from Japan's Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea. This approval, secured through Viatris's acquisition of Aculys Pharma, marks Japan's first histamine H3 receptor antagonist/inverse agonist for these conditions. While the approval presents a significant regulatory milestone and an opportunity to expand Viatris's innovative-medicines portfolio in Japan, its financial success will depend on pricing, market uptake, and profitability after licensing obligations and commercial spending.
Viatris Inc. stock falls Friday, underperforms market
Shares of Viatris Inc. (VTRS) fell 1.05% on Friday, closing at $16.95. This decline occurred despite a mixed day for the broader market, with the S&P 500 Index rising 0.17% and the Dow Jones Industrial Average falling 0.18%. The stock's performance ended a two-day winning streak.
Viatris Inc. (VTRS) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Viatris Inc. (VTRS), a pharmaceutical company. It highlights recent drug approvals, financial performance, analyst ratings, and various market insights related to the company's stock. The collection of articles offers a comprehensive overview of Viatris's current standing and market perception.
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Viatris Inc. has announced that Japan's Ministry of Health, Labour and Welfare approved WAKIX® (pitolisant) for treating excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) and for narcolepsy (type 1 and 2). This makes WAKIX, a histamine H3 receptor antagonist/inverse agonist, the first in its class to be approved in Japan for these conditions, addressing a significant unmet medical need. The approval is based on positive data from domestic Phase 3 clinical trials in Japan and various international studies.
Piper Sandler raises Viatris stock price target on patch growth By Investing.com
Piper Sandler has increased its price target for Viatris (NASDAQ: VTRS) shares to $13.00 from $12.00, maintaining a Neutral rating. The upgrade comes as Viatris's base business shows potential for top-line and EBITDA growth, particularly in its estradiol patch business, and ahead of Phase III readouts for key drugs cenerimod and selatogrel. Despite the raised target, the stock currently trades above this new target at $16.65, and the firm expresses caution about sustained growth without a biosimilars vertical.
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Gilead Sciences is accelerating global access planning for its investigational once-yearly lenacapavir for HIV prevention. The company has expanded its royalty-free voluntary licensing agreements with six manufacturers to include this new formulation, aiming to support manufacturing and supply in 120 high-incidence, resource-limited countries. This initiative, undertaken during Phase 3 trials, builds on Gilead's commitment to broaden access to HIV prevention options globally.
Viatris receives Japan approval for sleep disorder drug Wakix By Investing.com
Viatris Inc. announced that Japan's Ministry of Health, Labour and Welfare has approved Wakix (pitolisant) for treating excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy types 1 and 2. Wakix is the first histamine H3 receptor antagonist/inverse agonist to receive approval in Japan for these indications and is not classified as a controlled substance. The approval was based on data from domestic Phase 3 clinical trials and multiple international studies.
Viatris receives Japan approval for sleep disorder drug Wakix
Viatris Inc. announced that Japan's Ministry of Health, Labour and Welfare has approved Wakix (pitolisant) for treating excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy types 1 and 2. Wakix is the first histamine H3 receptor antagonist/inverse agonist approved in Japan for these indications and is not classified as a controlled substance. This approval was supported by data from domestic Phase 3 clinical trials in Japan and various international studies.
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Viatris Inc. announced that Japan's Ministry of Health, Labour and Welfare has approved WAKIX® (pitolisant) for treating excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy. WAKIX, a first-in-class histamine H3 receptor antagonist/inverse agonist, addresses a significant unmet medical need in Japan by offering a novel treatment option that is not classified as a controlled substance. This approval strengthens Viatris' innovative medicines portfolio in Japan, supported by positive data from domestic Phase 3 clinical trials and international studies.
Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating
Piper Sandler has increased its price target for Viatris (VTRS) to $13 from $12, while maintaining a Neutral rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article, published on MarketScreener, also lists recent news and analyst actions concerning Viatris, including other price target changes and company updates.
Sarepta Therapeutics (BOVESPA:S1RP34) - analisi del titolo
This article provides an analysis of Sarepta Therapeutics (BOVESPA:S1RP34), a biopharmaceutical company focused on developing therapies for rare diseases. It covers the company's financial overview, future growth predictions, past performance, and recent news, including FDA approvals, revenue guidance revisions, and clinical trial updates for its Duchenne muscular dystrophy treatments. The analysis highlights that the stock is trading significantly below its estimated fair value despite high volatility and expected earnings decrease.
Viatris, Long Chau launch lipid disorder management campaign
Viatris Vietnam and Long Chau Pharmacy & Vaccination System have partnered to launch the "Community Partnership for Lipid Care" campaign in Vietnam. This initiative aims to improve awareness, early detection, and management of lipid disorders, a major risk factor for cardiovascular disease, which accounts for a significant portion of deaths in Vietnam. The campaign will train approximately 1,000 pharmacists and reach three million people through community health activities and educational seminars.
VTRS - Viatris Inc Volatility & Greeks
This article provides a detailed financial overview of Viatris Inc. (VTRS), including its stock performance, market capitalization, key financial ratios, dividend information, and analyst recommendations. It highlights various metrics such as volatility, earnings per share, sales growth, and insider/institutional ownership. The data presented aims to give a comprehensive snapshot of the company's current financial health and market position.
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive
Viatris' Q2 earnings demonstrated strong financial health with increased net income, EPS, and doubled free cash flow, supporting shareholder returns through deleveraging, buybacks, and dividends. The company also shows promising pipeline progress and new product approvals, offering future growth optionality beyond its mature portfolio. Despite China-related uncertainties, improved guidance and an attractive valuation underpin a continued "Strong Buy" rating.
Leerink Partners Initiates Viatris at Outperform With $20 Price Target
Leerink Partners has initiated coverage on Viatris (VTRS) with an "Outperform" rating and a price target of $20. This positive analyst recommendation suggests that Leerink Partners expects the pharmaceutical company's stock to perform well. The article also notes recent news about Viatris, including Argus adjusting its price target to $20 and the company's Q2 2026 earnings report.
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating
Argus has increased its price target for Viatris (VTRS) to $20 from $18, while reiterating a Buy rating on the stock. This adjustment reflects the firm's positive outlook on the pharmaceutical company.
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC Filing - Form SCHEDULE 13G/A
FMR LLC and Abigail P. Johnson have disclosed an 11.0% passive stake in Viatris Inc (VTRS), totaling 126,764,446.45 shares of common stock as of August 31, 2026. This ownership was reported via an amended Schedule 13G/A filing. FMR LLC holds sole voting power over 113,359,609.44 shares, while both FMR LLC and Abigail P. Johnson have sole dispositive power over the entire reported stake.
